Stock viewCNBC-TV18
Glenmark shares rise after US arm launches cancer therapy
Positive+24
GreyOak summary
Glenmark Pharma shares gained up to 2% after its US arm launched a generic version of INLYTA tablets for kidney cancer treatment. The drug, originally developed by Pfizer, targets advanced disease cases.
What it affects
- Glenmark PharmaceuticalsGLENMARKPositive +24
Shares rose 2% after US drug launch.Rolling sentiment Negative -26
Source
Read the original at CNBC-TV18More Glenmark Pharmaceuticals news
- Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · Stock view ·
- Motilal Oswal sets Glenmark Pharma target at Rs 3000Moneycontrol · Company update ·